Equities research analysts expect Avrobio Inc (NASDAQ:AVRO) to report earnings of ($0.76) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Avrobio’s earnings, with estimates ranging from ($0.78) to ($0.70). Avrobio posted earnings of ($2.98) per share during the same quarter last year, which indicates a positive year over year growth rate of 74.5%. The firm is expected to report its next earnings report on Thursday, August 8th.
On average, analysts expect that Avrobio will report full year earnings of ($2.93) per share for the current year, with EPS estimates ranging from ($3.12) to ($2.54). For the next year, analysts expect that the company will post earnings of ($3.07) per share, with EPS estimates ranging from ($3.45) to ($2.65). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Avrobio.
Avrobio (NASDAQ:AVRO) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.01).
Institutional investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund acquired a new stake in Avrobio during the 4th quarter worth approximately $113,000. BlackRock Inc. lifted its position in Avrobio by 73.4% during the 4th quarter. BlackRock Inc. now owns 651,959 shares of the company’s stock worth $10,854,000 after acquiring an additional 276,018 shares during the period. Bank of New York Mellon Corp lifted its position in Avrobio by 60.6% during the 4th quarter. Bank of New York Mellon Corp now owns 25,937 shares of the company’s stock worth $431,000 after acquiring an additional 9,782 shares during the period. Citigroup Inc. lifted its position in Avrobio by 264.8% during the 4th quarter. Citigroup Inc. now owns 13,107 shares of the company’s stock worth $218,000 after acquiring an additional 9,514 shares during the period. Finally, Northern Trust Corp lifted its position in Avrobio by 2.8% during the 4th quarter. Northern Trust Corp now owns 79,211 shares of the company’s stock worth $1,319,000 after acquiring an additional 2,170 shares during the period. Institutional investors own 71.13% of the company’s stock.
AVRO stock traded down $1.45 during midday trading on Friday, hitting $21.99. The company’s stock had a trading volume of 821,445 shares, compared to its average volume of 534,508. Avrobio has a twelve month low of $11.85 and a twelve month high of $53.70. The business has a fifty day moving average price of $15.32. The firm has a market cap of $566.01 million and a PE ratio of -6.07.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Recommended Story: Initial Public Offering (IPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.